98% of pathologists surveyed are aware that SSA/P is a precursor lesion to colorectal cancer, the majority agree on diagnostic criteria, and a significant number feel that there needs to be greater communication and awareness among pathologists and gastroenterologists about SSA/P.
Endoscopic ultrasound (EUS) is increasingly used in the management of hepatobiliary lesions, allowing staging and tissue acquisition. It is operatordependent, and fine needle aspiration (FNA) of solid lesions provides an auditable standard; highvolume centres have shown excellent results for solid pancreatic lesion FNA with sensitivities of 92%-97%. The British Society of Gastroenterology guidelines stress that clinical quality should determine service provision, with geographical accessibility a secondary consideration. We set up the Wessex EUS network, working from a single hepatobiliary (HPB) pancreatic multidisciplinary team, with EUS provided in four local centres providing agreed standards and audit. Pancreatic solid lesion FNA results showed a pooled sensitivity of 94%, comparable with high-volume single centres. This demonstrates a network with good clinical governance is a plausible solution to providing a specialist service such as EUS and may be a roadmap that other specialist services under pressure could follow.
IntroductionRapid on site evaluation (ROSE) of cytology from endoscopic ultrasound fine-needle aspiration (EUS-FNA) is uncommon in the UK. The impact of ROSE in the learning curve of a new EUS-FNA service is largely unknown. Documenting the yield of malignancy in solid pancreatic lesions may provide a benchmark for performance of EUS-FNA.AimWe report the initial findings of ROSE and its impact on the first 36 consecutive cases of solid pancreatic mass lesions (SPML).MethodsWe prospectively collected data on the first 70 patients referred for an EUS-FNA incorporating a single endosonographer competent in radial EUS, a single cytotechnologist (ROSE) and two pathologists.ResultThe average age was 62.9 with a M/F ratio of 42:28. SPML accounted for 36/70 (51.4%). No samples were deemed inadequate. Cytology confirmed adenocarcinoma in 30/36 (83.3%). Of the remaining six, follow-up data (cytology, subsequent surgery, oncology, clinical follow-up) confirmed two cases consistent with chronic pancreatitis; one suspicious for malignancy (subsequent CT revealed lung metastases), while EUS criteria suggested malignancy in the remaining three cases cytology was non-diagnostic. One patient elected for a Whipples which showed pT3N1 pancreatic cancer, one remains under current surveillance follow-up, one died of metastatic tumour presumed pancreatic in origin. ROSE suggested malignancy in 34/36 (94%) cases. There was good agreement therefore between on site evaluation and final cytology reporting.ConclusionEUS FNA gave a high yield in the diagnosis of adenocarcinoma in solid pancreatic tumours in 30/34 (88%) one further case was suspicious for malignancy. ROSE had an immediate impact on determination of necrotic centres within tumour masses, immediate feedback on tissue acquisition and blood contaminating specimens thus guiding decisions re suction vs no suction, limiting the number of passes when material was deemed adequate thus optimising the procedure time, and guiding the evolving technique of FNA passes within a tumour mass. No case returned for a second EUS FNA. In a new FNA service ROSE contributed to the accuracy of staging, the learning curve of the team and enabled decision making to take place on the day of the procedure.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.